Biomarker deals

Biomarker deals

Caprion
Partner Deal description Date
Sunol Molecular Caprion received rights to develop antibodies in Phase I for hemolytic uremic syndrome (HUS) resulting from

Read the full 268 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE